Triple-negative breast cancer

Risk factors to potential targets

Bryan Schneider, Eric P. Winer, William D. Foulkes, Judy Garber, Charles M. Perou, Andrea Richardson, George W. Sledge, Lisa A. Carey

Research output: Contribution to journalArticle

288 Citations (Scopus)

Abstract

Triple-negative breast cancer has recently been recognized as an important subgroup of breast cancer with a distinct outcome and therapeutic approach when compared with other subgroups of breast cancer. Triple-negative breast cancer comprises primarily, but not exclusively, a molecu-larly distinct subtype of breast cancer, the basal-like subtype. We do not yet have an assay to identify basal-like breast cancer in clinical samples, so triple-negative breast cancer has become a commonly used proxy for this subtype. The molecular biology and pathophysiology of triple-negative breast cancer are not completely understood, but understanding is improving rapidly with the advent of sophisticated molecular biology platforms. Moreover, the established risk factors of breast cancer as a whole may not apply to this unique subgroup of patients. Finally, because triple-negative breast cancer is defined by the absence of a target, there are currently limitations to using a tailored therapeutic approach, leaving conventional cytotoxic therapies as the mainstay. Active preclinical and clinical research programs focus on defining the clinical behavior, delineating the risk factors, and more completely understanding the molecular biology of triple-negative breast cancer to improve prevention, optimize conventional agents, and unveil novel therapeutic targets. This CCR focus article will review the current state of the art on triple-negative breast cancer.

Original languageEnglish
Pages (from-to)8010-8018
Number of pages9
JournalClinical Cancer Research
Volume14
Issue number24
DOIs
StatePublished - Dec 15 2008

Fingerprint

Triple Negative Breast Neoplasms
Breast Neoplasms
Molecular Biology
Proxy
Therapeutics
Research

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Schneider, B., Winer, E. P., Foulkes, W. D., Garber, J., Perou, C. M., Richardson, A., ... Carey, L. A. (2008). Triple-negative breast cancer: Risk factors to potential targets. Clinical Cancer Research, 14(24), 8010-8018. https://doi.org/10.1158/1078-0432.CCR-08-1208

Triple-negative breast cancer : Risk factors to potential targets. / Schneider, Bryan; Winer, Eric P.; Foulkes, William D.; Garber, Judy; Perou, Charles M.; Richardson, Andrea; Sledge, George W.; Carey, Lisa A.

In: Clinical Cancer Research, Vol. 14, No. 24, 15.12.2008, p. 8010-8018.

Research output: Contribution to journalArticle

Schneider, B, Winer, EP, Foulkes, WD, Garber, J, Perou, CM, Richardson, A, Sledge, GW & Carey, LA 2008, 'Triple-negative breast cancer: Risk factors to potential targets', Clinical Cancer Research, vol. 14, no. 24, pp. 8010-8018. https://doi.org/10.1158/1078-0432.CCR-08-1208
Schneider B, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A et al. Triple-negative breast cancer: Risk factors to potential targets. Clinical Cancer Research. 2008 Dec 15;14(24):8010-8018. https://doi.org/10.1158/1078-0432.CCR-08-1208
Schneider, Bryan ; Winer, Eric P. ; Foulkes, William D. ; Garber, Judy ; Perou, Charles M. ; Richardson, Andrea ; Sledge, George W. ; Carey, Lisa A. / Triple-negative breast cancer : Risk factors to potential targets. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 24. pp. 8010-8018.
@article{d4b0df499a1e4d81a18fec02f529a540,
title = "Triple-negative breast cancer: Risk factors to potential targets",
abstract = "Triple-negative breast cancer has recently been recognized as an important subgroup of breast cancer with a distinct outcome and therapeutic approach when compared with other subgroups of breast cancer. Triple-negative breast cancer comprises primarily, but not exclusively, a molecu-larly distinct subtype of breast cancer, the basal-like subtype. We do not yet have an assay to identify basal-like breast cancer in clinical samples, so triple-negative breast cancer has become a commonly used proxy for this subtype. The molecular biology and pathophysiology of triple-negative breast cancer are not completely understood, but understanding is improving rapidly with the advent of sophisticated molecular biology platforms. Moreover, the established risk factors of breast cancer as a whole may not apply to this unique subgroup of patients. Finally, because triple-negative breast cancer is defined by the absence of a target, there are currently limitations to using a tailored therapeutic approach, leaving conventional cytotoxic therapies as the mainstay. Active preclinical and clinical research programs focus on defining the clinical behavior, delineating the risk factors, and more completely understanding the molecular biology of triple-negative breast cancer to improve prevention, optimize conventional agents, and unveil novel therapeutic targets. This CCR focus article will review the current state of the art on triple-negative breast cancer.",
author = "Bryan Schneider and Winer, {Eric P.} and Foulkes, {William D.} and Judy Garber and Perou, {Charles M.} and Andrea Richardson and Sledge, {George W.} and Carey, {Lisa A.}",
year = "2008",
month = "12",
day = "15",
doi = "10.1158/1078-0432.CCR-08-1208",
language = "English",
volume = "14",
pages = "8010--8018",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Triple-negative breast cancer

T2 - Risk factors to potential targets

AU - Schneider, Bryan

AU - Winer, Eric P.

AU - Foulkes, William D.

AU - Garber, Judy

AU - Perou, Charles M.

AU - Richardson, Andrea

AU - Sledge, George W.

AU - Carey, Lisa A.

PY - 2008/12/15

Y1 - 2008/12/15

N2 - Triple-negative breast cancer has recently been recognized as an important subgroup of breast cancer with a distinct outcome and therapeutic approach when compared with other subgroups of breast cancer. Triple-negative breast cancer comprises primarily, but not exclusively, a molecu-larly distinct subtype of breast cancer, the basal-like subtype. We do not yet have an assay to identify basal-like breast cancer in clinical samples, so triple-negative breast cancer has become a commonly used proxy for this subtype. The molecular biology and pathophysiology of triple-negative breast cancer are not completely understood, but understanding is improving rapidly with the advent of sophisticated molecular biology platforms. Moreover, the established risk factors of breast cancer as a whole may not apply to this unique subgroup of patients. Finally, because triple-negative breast cancer is defined by the absence of a target, there are currently limitations to using a tailored therapeutic approach, leaving conventional cytotoxic therapies as the mainstay. Active preclinical and clinical research programs focus on defining the clinical behavior, delineating the risk factors, and more completely understanding the molecular biology of triple-negative breast cancer to improve prevention, optimize conventional agents, and unveil novel therapeutic targets. This CCR focus article will review the current state of the art on triple-negative breast cancer.

AB - Triple-negative breast cancer has recently been recognized as an important subgroup of breast cancer with a distinct outcome and therapeutic approach when compared with other subgroups of breast cancer. Triple-negative breast cancer comprises primarily, but not exclusively, a molecu-larly distinct subtype of breast cancer, the basal-like subtype. We do not yet have an assay to identify basal-like breast cancer in clinical samples, so triple-negative breast cancer has become a commonly used proxy for this subtype. The molecular biology and pathophysiology of triple-negative breast cancer are not completely understood, but understanding is improving rapidly with the advent of sophisticated molecular biology platforms. Moreover, the established risk factors of breast cancer as a whole may not apply to this unique subgroup of patients. Finally, because triple-negative breast cancer is defined by the absence of a target, there are currently limitations to using a tailored therapeutic approach, leaving conventional cytotoxic therapies as the mainstay. Active preclinical and clinical research programs focus on defining the clinical behavior, delineating the risk factors, and more completely understanding the molecular biology of triple-negative breast cancer to improve prevention, optimize conventional agents, and unveil novel therapeutic targets. This CCR focus article will review the current state of the art on triple-negative breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=58149359842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149359842&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-1208

DO - 10.1158/1078-0432.CCR-08-1208

M3 - Article

VL - 14

SP - 8010

EP - 8018

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 24

ER -